發(fā)布時間：2018-05-11 20:49

  本文選題：型糖尿病 + 天麥消渴片　； 參考：《山東醫(yī)藥》2016年12期

【摘要】：目的探討天麥消渴片治療2型糖尿病(T2DM)的臨床效果及安全性。方法 132例新診斷、未治療的T2DM患者隨機分為天麥消渴片組68例及吡格列酮組64例,兩組均給予飲食、運動及二甲雙胍等治療,在此基礎(chǔ)上,天麥消渴片組口服天麥消渴片、吡格列酮組口服吡格列酮,均連續(xù)治療12周。治療前后分別測定兩組空腹血糖(FPG)、餐后2 h血糖(2 h PG)、空腹胰島素(FINS)、空腹C肽(FCP)、餐后2 h胰島素(2 h INS)、餐后2 h C肽(2 h CP)、糖化血紅蛋白(Hb A1c),及血脂、血壓、腰臀比(WHR)、肝功能、腎功能,計算胰島素抵抗指數(shù)(HCMA-IR)等。結(jié)果天麥消渴片組治療后WHR及FPG、2 h PG、Hb A1c、FINS、HOMA-IR水平均較治療前降低(P0.05或0.01),HOMA-β較治療前升高(P0.05);吡咯列酮組治療后FPG、2 h PG、Hb A1c、FCP、HOMA-IR水平均較治療前降低(P0.05或0.01)。天麥消渴片組治療后FPG、Hb A1c、HOMA-IR均低于吡格列酮組(P均0.05)。兩組治療后均未見明顯不良反應。結(jié)論天麥消渴片可改善初發(fā)T2DM患者胰島素敏感性,降低血糖、WHR和Hb A1c水平,且用藥安全。
[Abstract]:Objective to evaluate the efficacy and safety of Tianmaixiaoke tablet in the treatment of type 2 diabetes mellitus (T 2 DM). Methods 132 newly diagnosed and untreated T2DM patients were randomly divided into Tianmaixiaoke tablet group (n = 68) and pioglitazone group (n = 64). Both groups were treated with diet, exercise and metformin. Pioglitazone group was treated with pioglitazone for 12 weeks. Before and after treatment, fasting blood glucose (FPGN), postprandial blood glucose (2 h), plasma glucose (2 h), fasting insulin (FINSN), fasting C-peptide (FCPP), insulin (2 h), C-peptide (2 h), hemoglobin (HbA1c), blood lipids, blood pressure, waist-to-hip ratio (WHR), liver function, liver function were measured before and after treatment. Renal function, calculate insulin resistance index (HCMA-IRI) and so on. Results the levels of WHR and PGHbA1cFCPHOMA-IR in Tianmaixiaoke tablet group were significantly lower than those before treatment (P0.05 or 0.01), and the levels of PGHbA1cFCPHOMA-IR in pyrrolidone group were significantly lower than those before treatment (P0.05 or 0.01). In Tianmaixiaoke tablet group, the HOMA-IR of FPGN HbA1cFI was lower than that of pioglitazone group (P < 0.05). There was no obvious adverse reaction after treatment in both groups. Conclusion Tianmaixiaoke tablet can improve the insulin sensitivity, decrease the levels of blood glucose and HbA1c in patients with T2DM, and it is safe to use it.
【作者單位】： 中國醫(yī)科大學附屬第一醫(yī)院;
【基金】：遼寧省科學事業(yè)公益研究基金資助項目(2014001013)
【分類號】：R587.1

【相似文獻】

相關(guān)期刊論文 前10條

1 向慧;徐寒松;趙勝;;吡格列酮對2型糖尿病患者輕度認知功能障礙的影響及機制研究[J];中國現(xiàn)代醫(yī)學雜志;2011年20期

2 吳堅,鄒大進,劉保海;吡格列酮對2型糖尿病患者血漿內(nèi)皮素水平的影響[J];第二軍醫(yī)大學學報;2002年08期

3 汪啟迪,榮蓉,畢宇芳,趙詠桔,羅邦堯,劉超,狄福松,王德全,陳麗,蘇炳華,何清波,寧光;吡格列酮治療2型糖尿病的雙盲、隨機、平行對照多中心臨床研究[J];中國新藥與臨床雜志;2003年09期

4 劉寬芝 ,王曉英 ,李玉坤;吡格列酮在初診2型糖尿病病人中的臨床應用——附42例報告[J];新醫(yī)學;2004年02期

5 何煜,黃龍;吡格列酮治療2型糖尿病的療效觀察[J];廣西醫(yī)科大學學報;2004年06期

6 單利珍,任躍忠;吡格列酮的臨床研究進展[J];實用糖尿病雜志;2005年04期

7 任躍忠,宋作s，

本文編號：1875539